Recombinant Human DCPS protein(1-337 aa), His-tagged

• Cat.No.: DCPS-11862H
• Product Overview: Recombinant Human DCPS protein(1-337 aa), fused with N-terminal His tag, was expressed in E.coli.

Specification

• Species: Human
• Source: E.coli
• Tag: His
• Protein Length: 1-337 aa
• Form: The purified protein was Lyophilized from sterile PBS (58mM Na2HPO4,17mM NaH2PO4, 68mM NaCl, pH7.4). 5 % trehalose and 5 % mannitol are added as protectant before lyophilization. The elution buffer contain 300mM imidazole.
• AA Sequence: MADAAPQLGKRKRELDVEEAHAASTEEKEAGVGNGTCAPVRLPFSGFRLQKVLRESARDKIIFLHGKVNEASEDGDGEDAVVILEKTPFQVEQVAQLLTGSPELQLQFSNDIYSTYHLFPPRQLNDVKTTVVYPATEKHLQKYLRQDLRLIRETGDDYRNITLPHLESQSLSIQWVYNILDKKAEADRIVFENPDPSDGFVLIPDLKWNQQQLDDLYLIAICHRRGIRSLRDLTPEHLPLLRNILHQGQEAILQRYRMKGDHLRVYLHYLPSYYHLHVHFTALGFEAPGSGVERAHLLAEVIENLECDPRHYQQRTLTFALRADDPLLKLLQEAQQS
• Purity: 90%, by SDS-PAGE with Coomassie Brilliant Blue staining.
• Storage: Short-term storage: Store at 2-8°C for (1-2 weeks).
  Long-term storage: Aliquot and store at -20°C to -80°C for up to 3 months, reconstitution with sterile water and addition of an equal volume of glycerol. Avoid repeat freeze-thaw cycles.
• Reconstitution: Reconstitute at 0.25 μg/μl in 200 μl sterile water for short-term storage.
  After reconstitution with sterile water, if glycerol has no effect on subsequent experiments, it is recommended to add an equal volume of glycerol for long-term storage.

Gene Information

• Gene Name: DCPS decapping enzyme, scavenger [ Homo sapiens ]
• Official Symbol: DCPS
• Synonyms: DCPS; HSL1; HINT-5; HSPC015; decapping enzyme, scavenger ; scavenger mRNA-decapping enzyme DcpS; DCS-1; OTTHUMP00000231113; mRNA decapping enzyme; heat shock-like protein 1;histidine triad protein member 5; hint-related 7meGMP-directed hydrolase; homolog of C. elegans 7meGMP-directed hydrolase dcs-1; EC 3
• Gene ID: 28960
• mRNA Refseq: NM_014026
• Protein Refseq: NP_054745
• MIM: 610534
• UniProt ID: Q96C86

Case Study

Case 1: Meziane O, et al. Sci Rep. 2015

Human DcpS, a bifunctional mRNA decapping enzyme, regulates miRNA degradation via nucleocytoplasmic shuttling and collaborates with Xrn2 exonuclease, independent of its canonical scavenger activity. This conserved role in miRNA turnover highlights DcpS’s dual functionality in post-transcriptional gene regulation, offering insights into RNA metabolism and potential therapeutic targets for RNA-linked diseases.

Fig1. Inhibition of DcpS alters in vitro miRNA degradation.

Fig2. Cytoplasmic but not nuclear DcpS activates in vitro miRNA degradation.

Case 2: Shen V, et al. RNA. 2008

Human DcpS, a nucleocytoplasmic shuttling enzyme, regulates nuclear pre-mRNA splicing by modulating cap-binding complex (CBC) availability through cap hydrolysis. Depleting DcpS disrupts cap-proximal intron splicing via CBC sequestration, reversed by Cbp20 complementation, revealing its dual role in mRNA decay and RNA processing, expanding its functional scope in gene expression regulation.

Fig1. DcpS can displace Cbp20 from cap structure.

Fig2. DcpS affects the splicing efficiency of the rat fibronectin minigene reporter pre-mRNA first intron.

Application

1. Therapeutic Potential of Recombinant DCPS Protein in RNA Metabolism Disorders Recombinant DCPS (mRNA decapping enzyme) protein emerges as a key player in modulating RNA turnover and processing, with implications for cancers and neurodegenerative diseases. By regulating mRNA stability and splicing via cap hydrolysis, recombinant DCPS could restore dysregulated RNA metabolism in conditions like glioblastoma or Alzheimer’s, where aberrant RNA decay pathways contribute to pathogenesis. Preclinical studies suggest its utility in disrupting oncogenic mRNA networks or clearing toxic RNA aggregates, offering a novel RNA-targeted therapeutic strategy. 2. Diagnostic and Biomarker Development in Precision Medicine As a biomarker, recombinant DCPS aids in profiling RNA processing defects linked to disease progression. Its integration into in vitro assays enables detection of abnormal cap-binding complex (CBC) activity or splicing errors, supporting early diagnosis of RNA-linked disorders. Tissue-specific DCPS expression patterns, analyzed via high-throughput platforms, correlate with therapeutic resistance in cancers, guiding personalized treatment decisions and improving prognostic accuracy in precision oncology frameworks. 3. Advancing RNA-Targeted Drug Discovery and Research Tools Recombinant DCPS facilitates mechanistic studies on RNA decay and splicing regulation, critical for developing small-molecule inhibitors or gene therapies. High-throughput screens using DCPS identify compounds that modulate cap hydrolysis, potentially enhancing chemotherapy efficacy or mitigating neurotoxicity. Structural studies of DCPS-CBC interactions, enabled by recombinant protein tools, inform the design of RNA-processing modulators. Collaborative efforts explore DCPS’s synergy with CRISPR-based therapies, expanding its role in next-generation RNA therapeutics and biomarker-driven clinical trials.

Fig1. DCPS-mediated pre-mRNA metabolic pathway in UM by which disseminated cells gain enhanced malignant features to promote hepatic metastasis. (Bei Jin, 2023)